Georg B Landwehrmeyer1,2, Cheryl J Fitzer-Attas2, Joseph D Giuliano2, Nilza Gonçalves3, Karen E Anderson4, Francisco Cardoso5, Joaquim J Ferreira3, Tiago A Mestre6, Julie C Stout7, Cristina Sampaio2. 1. Department of Neurology University of Ulm Ulm Germany. 2. CHDI Management/CHDI Foundation Princeton New Jersey USA. 3. Faculty of Medicine University of Lisbon Lisbon Portugal. 4. MedStar Georgetown University Hospital & Georgetown University Medical Center-Huntington Disease Care, Education & Research Center Washington DC USA. 5. Movement Disorders Clinic, Medical School Universidade Federal de Minas Gerais Belo Horizonte Brazil. 6. Parkinson's disease and Movement Disorders Center Division of Neurology Department of Medicine The Ottawa Hospital Research Institute University of Ottawa Ottawa Ontario Canada. 7. School of Psychological Sciences Monash University Melbourne Victoria Australia.
Abstract
BACKGROUND: The study of complex neurodegenerative diseases is moving away from hypothesis-driven biological methods toward large scale multimodal approaches, requiring standardized collaborative efforts. Enroll-HD exemplifies such an integrated clinical research platform, designed and implemented to meet the research and clinical needs of Huntington's disease (HD). The aim of this study was to describe the unique organization of Enroll-HD and report baseline data analyses of its core study. METHODS: The Enroll-HD platform incorporates electronic data capture, biosampling, and a longitudinal observational study spanning four continents (ClinicalTrials.gov Identifier: NCT01574053). The primary study population includes HD gene expansion carriers (HDGECs; CAG expansion ≥36), subdivided into manifest/premanifest HD. The control population consists of genotype-negative first-degree relatives and family controls not genetically related. The study includes 10 core clinical assessments covering motor, cognitive, and behavioral domains. RESULTS: This data set comprises 1,534 participants (HDGEC = 1,071; controls = 463). Participant retention was high; 42 participants prematurely withdrew from the study. Mean ± standard deviation SD CAG repeat size was 43.5 ± 3.5 for HDGECs and 19.8 ± 3.4 for controls. Motor and behavioral assessments identified numerical differences between controls and HDGECs (manifest > premanifest > controls). Functional and independence assessments were generally similar for the premanifest and control groups with overlap in range of scores obtained. For the majority of cognitive tests, there were large differences between participants with manifest HD and all other groups. CONCLUSIONS: These first data from the Enroll-HD clinical research platform demonstrate the maturity and potential of the platform in collecting high-quality, clinically relevant data. Future data sets will be substantially larger as the platform expands longitudinally and regionally.
BACKGROUND: The study of complex neurodegenerative diseases is moving away from hypothesis-driven biological methods toward large scale multimodal approaches, requiring standardized collaborative efforts. Enroll-HD exemplifies such an integrated clinical research platform, designed and implemented to meet the research and clinical needs of Huntington's disease (HD). The aim of this study was to describe the unique organization of Enroll-HD and report baseline data analyses of its core study. METHODS: The Enroll-HD platform incorporates electronic data capture, biosampling, and a longitudinal observational study spanning four continents (ClinicalTrials.gov Identifier: NCT01574053). The primary study population includes HD gene expansion carriers (HDGECs; CAG expansion ≥36), subdivided into manifest/premanifest HD. The control population consists of genotype-negative first-degree relatives and family controls not genetically related. The study includes 10 core clinical assessments covering motor, cognitive, and behavioral domains. RESULTS: This data set comprises 1,534 participants (HDGEC = 1,071; controls = 463). Participant retention was high; 42 participants prematurely withdrew from the study. Mean ± standard deviation SD CAG repeat size was 43.5 ± 3.5 for HDGECs and 19.8 ± 3.4 for controls. Motor and behavioral assessments identified numerical differences between controls and HDGECs (manifest > premanifest > controls). Functional and independence assessments were generally similar for the premanifest and control groups with overlap in range of scores obtained. For the majority of cognitive tests, there were large differences between participants with manifest HD and all other groups. CONCLUSIONS: These first data from the Enroll-HD clinical research platform demonstrate the maturity and potential of the platform in collecting high-quality, clinically relevant data. Future data sets will be substantially larger as the platform expands longitudinally and regionally.
Entities:
Keywords:
Huntington's disease; observational study; research platform
Authors: Elisabeth M Kingma; Erik van Duijn; Reinier Timman; Rose C van der Mast; Raymund A C Roos Journal: Gen Hosp Psychiatry Date: 2008 Mar-Apr Impact factor: 3.238
Authors: Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout Journal: Lancet Neurol Date: 2009-07-29 Impact factor: 44.182
Authors: Peg Nopoulos; Eric A Epping; Tom Wassink; Bradley L Schlaggar; Joel Perlmutter Journal: Behav Brain Funct Date: 2011-10-18 Impact factor: 3.759
Authors: Mark Mühlau; Juliane Winkelmann; Dan Rujescu; Ina Giegling; Nikolaos Koutsouleris; Christian Gaser; Milan Arsic; Adolph Weindl; Maximilian Reiser; Eva M Meisenzahl Journal: PLoS One Date: 2012-01-03 Impact factor: 3.240
Authors: Jeffrey D Long; Douglas R Langbehn; Sarah J Tabrizi; Bernhard G Landwehrmeyer; Jane S Paulsen; John Warner; Cristina Sampaio Journal: Mov Disord Date: 2016-11-28 Impact factor: 10.338
Authors: Bryan Zeitler; Steven Froelich; Kimberly Marlen; David A Shivak; Qi Yu; Davis Li; Jocelynn R Pearl; Jeffrey C Miller; Lei Zhang; David E Paschon; Sarah J Hinkley; Irina Ankoudinova; Stephen Lam; Dmitry Guschin; Lexi Kopan; Jennifer M Cherone; Hoang-Oanh B Nguyen; Guijuan Qiao; Yasaman Ataei; Matthew C Mendel; Rainier Amora; Richard Surosky; Josee Laganiere; B Joseph Vu; Anand Narayanan; Yalda Sedaghat; Karsten Tillack; Christina Thiede; Annette Gärtner; Seung Kwak; Jonathan Bard; Ladislav Mrzljak; Larry Park; Taneli Heikkinen; Kimmo K Lehtimäki; Marie M Svedberg; Jenny Häggkvist; Lenke Tari; Miklós Tóth; Andrea Varrone; Christer Halldin; Andrea E Kudwa; Sylvie Ramboz; Michelle Day; Jyothisri Kondapalli; D James Surmeier; Fyodor D Urnov; Philip D Gregory; Edward J Rebar; Ignacio Muñoz-Sanjuán; H Steve Zhang Journal: Nat Med Date: 2019-07-01 Impact factor: 53.440
Authors: Ellen van der Plas; Douglas R Langbehn; Amy L Conrad; Timothy R Koscik; Alexander Tereshchenko; Eric A Epping; Vincent A Magnotta; Peggy C Nopoulos Journal: Neurology Date: 2019-08-01 Impact factor: 9.910
Authors: Kristina K Cain; Joseph L Flanigan; William Alex Dalrymple; James Patrie; Madaline B Harrison; Matthew J Barrett Journal: Mov Disord Clin Pract Date: 2021-03-30